JonesTrading analyst Debanjana Chatterjee maintained a Buy rating on Opus Genetics today and set a price target of $6.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Debanjana Chatterjee has given her Buy rating due to a combination of factors surrounding Opus Genetics’ promising developments. The company’s OPGx-BEST1 gene therapy program is showing potential, with early signs of structural benefits observed in preclinical models. This gene therapy targets patients with specific genetic profiles and intact photoreceptors, which could lead to significant improvements in their condition.
Moreover, the upcoming data release in the first quarter of 2026 is expected to provide insights from multiple patients, focusing on key clinical outcomes such as fluid resolution and retinal sensitivity improvements. Additionally, Opus Genetics is on track with its presbyopia program, which could result in a substantial milestone payment and future royalties. These strategic advancements and potential financial gains underpin Chatterjee’s optimistic outlook on the stock.
In another report released on October 16, Chardan Capital also initiated coverage with a Buy rating on the stock with a $9.00 price target.